Clinical Trial Update: Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of combining hepatic arterial infusion chemotherapy (HAIC) with TQB2868 and ramucirumab for second-l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Hepatic arterial infusion chemotherapy (HAIC) (hepatic arterial infusion chemotherapy)
• Ramucirumab (Cyramza) (ramucirumab)
• TQB2868

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab | Phase 2 | Status: NOT_YET_RECRUITING